These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 36071466)

  • 1. COVID-19 and cognitive impairment: neuroinvasive and blood‒brain barrier dysfunction.
    Chen Y; Yang W; Chen F; Cui L
    J Neuroinflammation; 2022 Sep; 19(1):222. PubMed ID: 36071466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 and Long COVID: Disruption of the Neurovascular Unit, Blood-Brain Barrier, and Tight Junctions.
    Kempuraj D; Aenlle KK; Cohen J; Mathew A; Isler D; Pangeni RP; Nathanson L; Theoharides TC; Klimas NG
    Neuroscientist; 2024 Aug; 30(4):421-439. PubMed ID: 37694571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurological manifestations of SARS-CoV-2: complexity, mechanism and associated disorders.
    Tyagi K; Rai P; Gautam A; Kaur H; Kapoor S; Suttee A; Jaiswal PK; Sharma A; Singh G; Barnwal RP
    Eur J Med Res; 2023 Aug; 28(1):307. PubMed ID: 37649125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroinvasion, neurotropic, and neuroinflammatory events of SARS-CoV-2: understanding the neurological manifestations in COVID-19 patients.
    Yachou Y; El Idrissi A; Belapasov V; Ait Benali S
    Neurol Sci; 2020 Oct; 41(10):2657-2669. PubMed ID: 32725449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe acute respiratory syndrome coronavirus 2 may be an underappreciated pathogen of the central nervous system.
    Alam SB; Willows S; Kulka M; Sandhu JK
    Eur J Neurol; 2020 Nov; 27(11):2348-2360. PubMed ID: 32668062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Caveolin-1 mediates blood-brain barrier permeability, neuroinflammation, and cognitive impairment in SARS-CoV-2 infection.
    Trevino TN; Almousawi AA; Robinson KF; Fogel AB; Class J; Minshall RD; Tai LM; Richner JM; Lutz SE
    J Neuroimmunol; 2024 Mar; 388():578309. PubMed ID: 38335781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuro-COVID-19: an insidious virus in action.
    Bratosiewicz-Wąsik J
    Neurol Neurochir Pol; 2022; 56(1):48-60. PubMed ID: 34642927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence of central nervous system infection and neuroinvasive routes, as well as neurological involvement, in the lethality of SARS-CoV-2 infection.
    Liu JM; Tan BH; Wu S; Gui Y; Suo JL; Li YC
    J Med Virol; 2021 Mar; 93(3):1304-1313. PubMed ID: 33002209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19-Associated Neurological Disorders: The Potential Route of CNS Invasion and Blood-Brain Relevance.
    Achar A; Ghosh C
    Cells; 2020 Oct; 9(11):. PubMed ID: 33120941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurological manifestations of patients with COVID-19: potential routes of SARS-CoV-2 neuroinvasion from the periphery to the brain.
    Li Z; Liu T; Yang N; Han D; Mi X; Li Y; Liu K; Vuylsteke A; Xiang H; Guo X
    Front Med; 2020 Oct; 14(5):533-541. PubMed ID: 32367431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 journey to the brain with a focus on potential role of docosahexaenoic acid bioactive lipid mediators.
    Hachem M
    Biochimie; 2021 May; 184():95-103. PubMed ID: 33639198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2: is there neuroinvasion?
    McQuaid C; Brady M; Deane R
    Fluids Barriers CNS; 2021 Jul; 18(1):32. PubMed ID: 34261487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurological manifestations and pathogenic mechanisms of COVID-19.
    Galea M; Agius M; Vassallo N
    Neurol Res; 2022 Jul; 44(7):571-582. PubMed ID: 34986754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 associated nervous system manifestations.
    Khatoon F; Prasad K; Kumar V
    Sleep Med; 2022 Mar; 91():231-236. PubMed ID: 34321155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 Poorly Replicates in Cells of the Human Blood-Brain Barrier Without Associated Deleterious Effects.
    Constant O; Barthelemy J; Bolloré K; Tuaillon E; Gosselet F; Chable-Bessia C; Merida P; Muriaux D; Van de Perre P; Salinas S; Simonin Y
    Front Immunol; 2021; 12():697329. PubMed ID: 34386007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anatomical barriers against SARS-CoV-2 neuroinvasion at vulnerable interfaces visualized in deceased COVID-19 patients.
    Khan M; Clijsters M; Choi S; Backaert W; Claerhout M; Couvreur F; Van Breda L; Bourgeois F; Speleman K; Klein S; Van Laethem J; Verstappen G; Dereli AS; Yoo SJ; Zhou H; Dan Do TN; Jochmans D; Laenen L; Debaveye Y; De Munter P; Gunst J; Jorissen M; Lagrou K; Meersseman P; Neyts J; Thal DR; Topsakal V; Vandenbriele C; Wauters J; Mombaerts P; Van Gerven L
    Neuron; 2022 Dec; 110(23):3919-3935.e6. PubMed ID: 36446381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 induces blood-brain barrier and choroid plexus barrier impairments and vascular inflammation in mice.
    Qiao H; Deng X; Qiu L; Qu Y; Chiu Y; Chen F; Xia S; Muenzel C; Ge T; Zhang Z; Song P; Bonnin A; Zhao Z; Yuan W
    J Med Virol; 2024 May; 96(5):e29671. PubMed ID: 38747003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can SARS-CoV-2 infect the central nervous system via the olfactory bulb or the blood-brain barrier?
    Burks SM; Rosas-Hernandez H; Alejandro Ramirez-Lee M; Cuevas E; Talpos JC
    Brain Behav Immun; 2021 Jul; 95():7-14. PubMed ID: 33412255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 and neurodegenerative diseases.
    Fu YW; Xu HS; Liu SJ
    Eur Rev Med Pharmacol Sci; 2022 Jun; 26(12):4535-4544. PubMed ID: 35776055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroinvasion of SARS-CoV-2 may play a role in the breakdown of the respiratory center of the brain.
    Dey J; Alam MT; Chandra S; Gupta J; Ray U; Srivastava AK; Tripathi PP
    J Med Virol; 2021 Mar; 93(3):1296-1303. PubMed ID: 32964419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.